[
  {
    "ts": "2025-09-09T18:22:00+00:00",
    "headline": "Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.",
    "summary": "Biotech stocks are on a  winning streak that might just continue through the rest of the year.  When the biotech sector shows signs of renewed strength, it often signals a broader risk-on sentiment among investors.  The biotech ETF, up 5% in 2025, is poised for its third consecutive annual percent gain in the single digits.",
    "url": "https://www.barrons.com/articles/biotech-stocks-incyte-merus-crispr-d56d1cf9?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f0584c96-64e0-3d46-b799-60b944de6059",
      "content": {
        "id": "f0584c96-64e0-3d46-b799-60b944de6059",
        "contentType": "STORY",
        "title": "Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.",
        "description": "",
        "summary": "Biotech stocks are on a  winning streak that might just continue through the rest of the year.  When the biotech sector shows signs of renewed strength, it often signals a broader risk-on sentiment among investors.  The biotech ETF, up 5% in 2025, is poised for its third consecutive annual percent gain in the single digits.",
        "pubDate": "2025-09-09T18:22:00Z",
        "displayTime": "2025-09-09T18:22:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f0584c96-64e0-3d46-b799-60b944de6059/biotech-sector-shows-no-signs.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/ae29c7ae73faab79d65da58beec09029",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7m1dTaXqDTaC6DK2UYIj.A--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/ae29c7ae73faab79d65da58beec09029.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QkqlM8GGFQ__5BLgKdxvBw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/ae29c7ae73faab79d65da58beec09029.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/biotech-stocks-incyte-merus-crispr-d56d1cf9?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XLV"
            },
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "INCY"
            },
            {
              "symbol": "XBI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]